IMRX: Immuneering Corporation - Class A

IMRX新闻

• Investing 13:22 Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock
• Investing 13:01 Immuneering director Hausman buys IMRX stock worth $19,862
• Investing 09:01 Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data
• Investing 11:25 Immuneering stock price target raised to $10 at Mizuho on cancer drug data
• Investing 11:58 Immuneering stock rises after positive pancreatic cancer trial data
• Investing 10:05 Immuneering reports promising pancreatic cancer trial results
• Investing 12:12 Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
• Investing 12:28 Immuneering to Present at the Jefferies Global Healthcare Conference